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Abstract
Background: The purpose of this study was to assess the expression levels for TbRI, TbRII, and TbRIII in epithelial
layers of oral premalignant lesions (oral leukoplakia, OLK) and oral squamous cell carcinoma (OSCC), as well as in
oral carcinoma-associated fibroblasts (CAFs), with the final goal of exploring the roles of various types of TbRs in
carcinogenesis of oral mucosa.
Methods: Normal oral tissues, OLK, and OSCC were obtained from 138 previously untreated patients. Seven
primary human oral CAF lines and six primary normal fibroblast (NF) lines were established successfully via cell
culture. The three receptors were detected using immunohistochemical (IHC), quantitative RT-PCR, and Western
blot approaches.
Results: IHC signals for TbRII and TbRIII in the epithelial layer decreased in tissue samples with increasing disease
aggressiveness (P < 0.05); no expression differences were observed for TbRI, in OLK and OSCC (P > 0.05); and TbRII
and TbRIII were significantly downregulated in CAFs compared with NFs, at the mRNA and protein levels (P <
0.05). Exogenous expression of TGF-b1 led to a remarkable decrease in the expression of TbRII and TbRIII in CAFs
(P < 0.05).
Conclusion: This study provides the first evidence that the loss of TbRII and TbRIII expression in oral epithelium
and stroma is a common event in OSCC. The restoration of the expression of TbRII and TbRIII in oral cancerous
tissues may represent a novel strategy for the treatment of oral carcinoma.
Background
An increasing number of studies demonstrate that
transforming growth factor beta (TGF-b) signaling path-
way plays a dual role during the initiation and progres-
sion of human cancer; initially, it suppresses the
formation of tumors, but elevated levels of TGF-b pro-
mote the growth, progression, and migration of estab-
lished tumors. Different explanations have been
proposed for this dichotomous function of TGF-b,
including the possibility that TGF-b exerts tumor-
suppressing effects on epithelial-derived tumor cells and
tumor-promoting effects on stromal cells [1]. In general,
TGF-b exerts its effect by binding to the TGF-b type II
receptor (TbRII) and by subsequently recruiting TbRI
for downstream cytoplasmic signaling via multiple paral-
lel signaling pathways, including the SMAD proteins [2].
In addition, TbRIII functions as a coreceptor to increase
the binding of ligands to TbRII. In a majority of human
cancers and cell lines, the expression of TbRI and TbRII
is altered at the protein and/or mRNA levels [3,4].
The in-depth study of TbRIII revealed that this recep-
tor may have additional functions that are independent
of ligand presentation. Ryan et al [5] showed that the
expression of TbRIII (or betaglycan) is downregulated
or lost in human prostate cancers compared with benign
prostate tissues, at the mRNA and protein levels.
Recently, another group used in vitro cell culture and in
vivo animal models to demonstrate that the restoration
of TbRIII expression in renal cell carcinoma resulted in
a marked induction of apoptosis [6].
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Human oral squamous cell carcinoma (OSCC)
accounts for about 90% of malignant oral lesions. It is
widely recognized as progressing in a multistep manner,
with an initial presentation of premalignant lesions
(among which oral leukoplakia (OLK) is the most com-
mon), and later development of hyperplasia and dyspla-
sia, then in situ carcinoma, and finally invasive
carcinoma [7]. However, the expression of the major
components of the pathway, which include the systema-
tic analysis of signaling receptors TbRI, TbRII, and
TbRIII, remains intact in human OSCC [8,9]. The cur-
rent study represents the first systematic analysis of the
expression of TbRI, TbRII, and TbRIII during the pro-
cess of oral epithelial carcinogenesis.
Recent studies strongly suggest that the clinical beha-
vior of malignant tumors not only depends on altera-
tions in the epithelial cells themselves, but is also
affected by their interaction with the tumor-associated
stroma. However, the components of these specialized
stromal cells represent a complex network that includes
inflammatory cells (lymphocytes, macrophages, and
mast cells), activated fibroblasts, and cells comprising
the vasculature. Therefore, it remains questionable
whether one single factor will be the “magic bullet” of
cancer therapy. Recent data bring prominence to the
idea that activated fibroblasts (also termed carcinoma-
associated fibroblasts (CAFs) or myofibroblasts) may be
major players in the tumor stromal environment [10,11].
Their role as starting or supportive elements in carcino-
genesis is also well established. Relevant studies of mod-
ified fibroblasts have been performed in several tumor
systems [12,13]. Some of the systematic and important
findings of our previous study suggest that oral CAFs
promote the proliferation and invasion of the lingual
carcinoma cell line Tca8113 in vitro by secreting the
KGF (keratinocyte growth factor) and MMP-2 factors
(matrix metalloproteinase) [14]. A recent study showed
that TGF-b signaling in fibroblasts modulated the
growth and oncogenic potential of adjacent epithelia in
selected tissues [15]. Moreover, downregulation of
TbRII was observed in colon-carcinoma-associated spin-
dle-like stroma cells that apparently represented fibro-
blasts and myofibroblasts [14,16]. In our study, we
directly separated and cultured oral CAFs in vitro from
adjacent OSCC tissues and evaluated, for the first time,




All surgically resected tissue specimens were obtained
from the West China Hospital of Stomatology. For IHC
analyses, 138 specimens representing four different clini-
copathological stages (including 25 normal epithelium
tissues, 21 OLK samples without dysplasia, 24 OLK
samples with dysplasia, and 68 infiltrated OSCCs) were
recruited from the archives of the Department of Oral
Surgery and Oral Medicine. The 138 specimens included
eight OSCC samples and paired normal tissues. The
corresponding normal tissues were incised along a line
that is surgically termed a safety border, which was veri-
fied via staining of frozen sections. All surgically
resected tissues were collected, fixed in formalin, and
embedded in paraffin for histopathological confirmation.
For primary cell cultivation, fresh and sterile tissue
specimens (including OSCC and normal oral mucosal
tissues) were placed immediately on Hanks Balanced
Salt Solution (Gibco, USA) containing penicillin and
streptomycin (200 μg/ml) after being collected from the
patient. All samples contained the epithelium and adja-
cent connective tissues. The OSCC specimen was fresh
and exhibited infiltration of the adjacent connective tis-
sue. Connective tissues used for sectioning were col-
lected as close as possible to the epithelium. The
protocol was reviewed by the Institutional Ethics Com-
mittee of Sichuan University and informed consent was
obtained from each patient.
IHC Analysis
Immunostaining for TbRI and TbRII (rabbit polyclonal
antibodies; dilution, 1:200; Santa Cruz, USA) and TbRIII
(mouse monoclonal antibody; dilution, 1:200; Santa Cruz,
USA) in human OSCC and tumor-associated stromal
sections was performed using the DakoCytomation EnVi-
sion system (DakoCytomation Corporation, Carpinteria,
CA), according to the manufacturer’s instructions. Slides
were counterstained with Modified Harris Hematoxylin.
Immunoreactivity was scored as “-” (absent), “1+” (low, ≤
25% of positive cells), “2+” (moderate, 26-75% of positive
cells), or “3+” (diffuse, > 75% of positive cells) [9]. OSCCs
were assessed based on at least 10 randomly selected
fields. All slides were interpreted by two investigators.
Isolation and Cultivation of Oral CAFs and NFs
The specimens were analyzed using methods described
previously[14]. Briefly, tissues were washed twice with
phosphate-buffered saline (PBS) and antibiotics. Oral
epithelial and adipose tissues were then separated from
surrounding stromal cells. The residual connective tissue
was cut into small pieces (1 × 1 × 1 mm) that were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco, USA, pH 7.2) containing 20% fetal calf
serum (Gibco, USA), glutamine (20 μg/ml), penicillin
(100 U/ml), streptomycin (100 μg/ml), and 0.25% trypsi-
nase (Gibco) at 37°C in an atmosphere containing 5%
CO2. To purify the cells, we opted for a method of cur-
ettage combined with trypsinization, which was per-
formed when cells covered the bottom of the culture
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bottle fully. Cultures at passage number three were used
for the cellular identification of oral CAFs and NFs.
A wide-spectrum a-cytokeratin antibody (ZSGB-BIO,
Beijing, Corp., China) was used to confirm the absence
of contaminating epithelial cells. Finally, antibodies
against vimentin (ZSGB-BIO, Beijing, Corp., China) and
smooth muscle a-actin (R&D Systems) were used to
confirm the myofibroblastic nature of these cells [17].
Quantitative Real-Time PCR
Total RNA was isolated from cells using the Trizol
reagent (Invitrogen) and was quantified by analysis of
absorbance at 260 nm. Relative gene expression levels
were calculated using the comparative threshold-cycle
method of quantitative PCR, with data normalized to
b-actin and expressed relative to untreated controls.
Real-time PCR was performed using the SYBR Prime-
Script™RT-PCR kit II (TaKaRa, Dalian, China), accord-
ing to the manufacturer’s instructions. The primers used
to amplify TbRI, TbRII, and TbRIII were as follows:
TbRI sense, 5’-GGTCTTGCCCATCTTCACAT-3’ and
antisense, 5’-TCTGTGGCTGAATCATGTCT-3’; TbRII
sense, 5’-GTCTACTCCATGGCTCTGGT-3’ and anti-
sense, 5’-ATCTGGATGCCCTGGTGGTT-3’; and
TbRIII sense, 5’-TACAGAGAGAGGTCACACT-3’ and
antisense 5’-GTCTTCAGATGCCACACCAG-3’. The
total volume used in PCR was 50 μL. PCR products
(5 μl) were analyzed by electrophoresis using 1.5% agar-
ose gels and were visualized by SYBR Gold (Molecular
Probes, Eugene, USA) staining. All experiments were
performed in triplicate.
Protein Preparation and Western Blot Analysis
Protein extracts were prepared using a lysis buffer
(RIPA) containing the protease inhibitor PMSF (RIPA:
PMSF = 50:1). For Western blot analysis, ~80 μg of pro-
tein was separated using 8% SDS-PAGE, which was fol-
lowed by transfer onto a PVDF membrane (Millipore,
USA) and probing with an anti-TbR antibody (1:400,
Santa Cruz, USA). The blots were incubated with horse-
radish-peroxidase-conjugated secondary antibodies
(1:5,000) and visualized using an enhanced chemilumi-
nescence detection system (Pierce Biotech Inc.,
Rockford, IL).
Preparation of Cells Conditioned With the Human TGF-b1
Cytokine
To determine whether TGF-b1 mediates the regulation
of the expression of TbRI, TbRII, and TbRIII, we
assessed the levels of the TbRs using quantitative real-
time PCR and Western blot analysis after treatment
with TGF-b1.
TGF-b1 was obtained from Sigma (St. Louis, MO).
CAFs or NFs cells were cultured for two consecutive
days in medium containing 10% fetal calf serum and
were then washed twice with PBS and cultured in
serum-free medium containing 10 ng/ml of TGF-b1.
After 24 h of treatment, cells were washed and har-
vested for RNA and protein extraction.
Statistical Analyses
Differences between the groups were statistically evalu-
ated using the unpaired Student’s t test. The chi-squared
or K Independent Samples Tests were used to compare
frequencies, when appropriate. Significance was set at
P < 0.05. All analyses were performed using the statisti-
cal software SPSS for Windows Version 13 (SPSS Inc.,
Chicago, USA).
Results
Expression of TbRI, TbRII, and TbRIII in Human OSCC, Oral
Leukoplakia, and Normal Tissues
To fully assess the expression of TbRI, II, and III in
clinical samples and determine their role in OSCC carci-
nogenesis and prognosis, 138 specimens were examined
that represented four clinicopathological stages (includ-
ing normal epithelium tissues, OLK without dysplasia,
OLK with dysplasia, and infiltrated OSCCs). The clinical
information of patients is shown in Table 1.
Our IHC results showed moderate-to-intense homoge-
neous cytoplasmic or membrane expression of TbRI, II,
and III in oral normal squamous epithelium. Homoge-
neous, moderate, and intense cytoplasmic expression of
TbR-I was observed in OSCC tissues and in OLK
(Figure 1A-D; Figure 2A). However, TbRII and TbRIII
staining in the four groups revealed a remarkable
decrease in expression from normal oral specimens
through OLK to OSCC (Figure 1E-L; Figure 2B and 2C),
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Figure 1 The expression of TbRI, TbRII and TbRIII in human oral squamous carcinoma. TbRI in OSCC tissues and in OLK showed the same
homogeneous, moderate, and intense cytoplasmic expression as in normal oral specimens (A-D). IHC analysis showed that the expression of
TbRII (E-H) and TbRIII (I-L) decreased gradually with the progression of carcinogenesis. (E) Strong signal for TbRII was detected in the upper
spinous and granular layers of normal specimens. (F) Positive staining was detected mainly in the granular layers and in cuticular layer
(arrowhead) in OLK without dysplasia. (G) The immunostaining profile was decreased in OLK with dysplasia. (H) Significant downregulation of
TbRII was observed in infiltrated OSCC. (I) Strong signal for TbRIII was detected in the basal layer and in the upper spinous in normal specimens
(arrowhead). (J) Positive staining was significantly decreased in OLK without dysplasia and a stronger signal for TbRIII was detected in the basal
layer. (K) The immunostaining profile was decreased in OLK with dysplasia. (L) Note the absence of TbRIII staining in OSCC tissues. Weak
expression of TbRIII was observed in OSCC stroma exclusively. (F) IHC scores for TbRI in patient-matched normal and OSCC samples.
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which was paralleled by an increase in the severity of
epithelium dysplasia. Interestingly, we noted the upregu-
lation of TbRIII at the basal layer, both in normal
epithelium and oral leukoplakia (Figure 1 I(2), J(2)),
whereas TbRII expression was nearly absent in the two
oral epithelia. However, a strong signal for TbRII was
detected in the upper spinous and granular layers of
normal oral epithelium, as well as in the cuticular layer,
especially in the OLK cases (Figure 1F). The proportion
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Figure 2 Summary of IHC results, with percentages shown. (A:TbRI) P = 0.116, K Independent Samples Tests. (B:TbRII) **P = 0.002, K
Independent Samples Tests. (C: TbRIII) ***P < 0.001, K Independent Samples Tests. When staining is not detected, we stated in the figure (0).
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from 24% in normal oral specimens to 10.3% in OSCC
specimens. Concomitantly, the proportion of cells exhi-
biting low TbRII expression increased from 0% in nor-
mal oral specimens to 32.4% in OSCC specimens (P =
0.002, K Independent Samples Tests) (Figure 2B). The
number of cells exhibiting diffuse TbRIII expression
decreased from 24% in normal specimens to 9.5% in
OLK without dysplasia and 8.3% in OLK with dysplasia,
and to 4.4% in OSCC specimens. In contrast, the pro-
portion of cells with low TbRIII expression increased
from 4% in normal specimens to 23.8% in OLK without
dysplasia and 33.3% in OLK with dysplasia, and to
39.7% in OSCC specimens (P < 0.001, K Independent
Samples Tests) (Figure 2C). In addition, to address
directly the role of the loss of TbR expression in OSCC
progression, we assessed eight matched normal tissue
samples and invasive OSCC specimens (Figure 3). The
examination of TbRII expression revealed that six cases
exhibited a decrease in expression, from relatively high
levels (IHC score, 2-3) in normal oral tissues to low
expression levels (IHC score, 0-1) in the matching inva-
sive OSCC tissues (Figure 3B). TbRIII expression
decreased from an IHC score of 2-3 in normal speci-
mens to a score of 0 in OSCC specimens (Figure 3C).
These data suggest that the expression of both TbRII
and TbRIII was significantly downregulated in OSCC
samples and that this loss of TbRII and TbRIII expres-
sion correlated with the development of OSCC (from
normal tissues through OLK to OSCC).
Identification of Oral CAFs and NFs
Seven primary human oral CAF lines and six primary
oral NF lines were derived from oral mucosa successfully
using cell culture. The clinical information of the OSCC
patients used for the establishment of primary CAF cul-
tures is listed in Table 2. Normal tissues used for NF cul-
ture were collected from healthy individuals undergoing
plastic or trauma surgery. We then verified the purity of
the various fibroblast populations using immunostaining.
These fibroblast populations were negative for cytokera-
tin, whereas they expressed fibroblastic marker vimentin,
which suggests that some fibroblast traits were preserved
in the CAFs (Figure 4). Importantly, cultured CAFs
expressed traits of activated fibroblasts (myofibroblasts).
Expression of alpha smooth muscle actin (a-SMA) is a
defining characteristic of CAFs [10]. Using an anti-
a-SMA antibody, we observed an increased proportion
of a-SMA-positive myofibroblasts in isolated CAF popu-
lations (Figure 4) compared with normal fibroblasts.
Loss of TbRII and TbRIII Expression in CAFs Assessed
Using RT-PCR and Western Blotting
The mRNA expression levels of the three kinds of TbRs
in CAFs and NFs were examined using quantitative
real-time PCR. The expression of the TbRIII mRNA in
CAFs was downregulated by a factor of 11.37 and was
significantly different from the control group (P =
0.001). In addition, the expression of the TbRII mRNA
was reduced by a factor of 2.013 in CAFs compared
with NFs (P = 0.004). TbRI mRNA expression levels
were not significantly different between CAFs and NFs
(P = 0.362). Overall, the expression levels of the TbRI,
TbRII, and TbRIII mRNAs, as assessed using RT-PCR
analysis, were consistent with the immunocytochemistry
results (Figure 5). Similarly, the expression of TbRII and
TbRIII was decreased at the protein level in CAF cells
compared with normal fibroblasts (Figure 6). No signifi-
cant changes were observed regarding TbRI protein
expression levels.
TGF-b1 Downregulated the Expression of TbRII and TbRIII
in Oral CAFs and in NFs
Our results showed that TbRIII and TbRII were signifi-
cantly downregulated in oral CAFs or in NFs after treat-
ment with 10 ng/ml TGF-b1, with a maximal
downregulation at 6-12 h (Figure 5B-G). To assess
whether the effects of TGF-b1 on the expression levels
of TbRII and TbRIII were specific, we analyzed the role
of TGF-b1 in the regulation of TbRI levels in oral
CAFs. In contrast with the results obtained for TbRIII
and TbRII, TGF-b1 treatment led to a slight increase in
the levels of TbRI (this result was not significant)
(Figure 5A). Besides, TGF-b1 could also downregulate
the TbRIII and TbRII expression in NFs (Figure 6D).
These results indicate that transcriptional and transla-
tional downregulation associated with increased expres-
sion of TGF-b1 in an oral cancer microenvironment
(especially in CAFs) may represent a mechanism that
leads to oral carcinogenesis. We found that TGF-b1
downregulated TbRII and TbRIII (and not only TbRIII)
in oral CAFs and in NFs.
Discussion
This study represents the first systematic demonstration
of the downregulation of the TGF-b receptors TbRII
and TbRIII in human OSCC, with approximately 35.3%
of OSCC specimens demonstrating low or absent
expression of TbRII and approximately 52.9% of speci-
mens demonstrating low or absent expression of TbRIII.
This decrease in the expression levels of TbRII and
TbRIII correlated with the progression of OSCC. We
also demonstrated that loss of TbRII and TbRIII expres-
sion was an early event that occurred initially during the
OLK stage. However, there was no significant difference
in TbRI expression between normal specimens and
OLK or OSCC. Thus, we predict that loss of TbRII and
TbRIII expression is the most common alteration in the
TGF-b signaling pathway described in human OSCC.
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Studies performed on other tumor tissues regarding
TGF-b receptors yielded similar results, and it has been
described as having an association with carcinogenesis
and tumorprogression [16,18,19]. Previous data showed
TbRIII can enhance TGFb-mediated inhibition of
proliferation, invasion and angiogenesis. Reexpression of
TbRIII in vivo in renal cell carcinoma models induced
striking apoptosis [6]. These results were consistent with
our current study of tumor progression of oral cancer
cells in which TGF-b receptors were defective. The
Figure 3 IHC scores for TbRI, TbRII and TbRIII in patient-matched normal and OSCC samples.
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potential mechanism underlying these findings may be
that the decreased expression of the two receptors leads
to the decrease of TbRII- or TbRIII-mediated apoptosis.
These studies, together with the present study, suggest a
broad role for both TbRII or TbRIII as tumor suppres-
sors in epithelial-derived malignancies.
Tumor occurrence and development are intrinsically
correlated with the role of the surrounding stroma. In
the current study, we demonstrated that TbRII and
TbRIII played an important role in oral carcinogenesis.
Did similar changes take place in tumor-associated
stroma? Considering the complex composition of
stroma, we chose to study CAFs as the object of our
study, as these cells are considered crucial in the process
of carcinogenesis. Carcinoma-associated fibroblasts
(CAFs) have been regarded as a special kind of myofi-
broblasts, and they also were named as myofibroblasts
in many reports [10,13,20,21]. The stromal microenvir-
onment in human tumours play a key role in the forma-
tion of CAFs. This cell-type is mostly defined based on
morphological characteristics, biological behavior
(including promotion of tumor cell growth) [13] or the
expression of markers such as a-smooth-muscle actin
(a-SMA), fibroblast-activated protein (FAP), fibroblast-
specific protein-1 (FSP1), neuron-glial antigen-2 (NG2)
and PDGF b-receptor [10]. However, and a-SMA was
mainly used to identify the CAFs [10,13,20,21]. In our
study, the oral CAFs was also detected as expression of
a-SMA. To verify our hypothesis, we first isolated and
cultured seven primary CAF lines and then assessed the
expression levels of TbRI, TbRII, and TbRIII. Coupled
with the IHC observations from OSCC, both TbRII and
TbRIII were downregulated frequently at the mRNA
and protein levels in human oral CAFs compared with
NFs. A more pronounced decline was observed for the
expression of TbRIII compared with TbRII (11.37 fold
vs 2.013 fold). Bacman D et al considered that the
decrease of TGF-b receptor expression in stroma as in
epithelial tumour tissue might occur via mutation or
downregulation [16]. In addition, significant downregu-
lation of TbRII and TbRIII was observed after treatment
with TGF-b1 for varying periods. Although we observed
a slight increase in TbRI expression, this observation
was neither consistent nor significant. The mechanisms
underlying the negative regulation mediated by TGF-b1
implicate primarily genes that regulate the cell cycle,
including the downregulation of growth-promoting tran-
scription factors, such as c-Myc, ID1, and ID2 [22].
TGF-b isoforms downregulate TbRIII in breast cancer
cells; this effect was relatively specific for TbRIII, as it
did not affect TbRI and TbRII [19,23]. However, here
we demonstrated the loss of TbRIII and TbRII expres-
sion both in CAFs and in NFs after treatment with
TGF-b1. The previous report together with our current
discoveries lead us to conclude that loss of the expres-
sion of TbRIII and/or TbRII in CAFs is a mechanism
that underlies the tumor-promoting function of TGF-
b1. How might the changes in the cellular characteris-
tics of CAFs, together with the loss of TbRII and TbRIII
expression and their response to TGF-b1, affect oral
carcinogenesis? The current results prompt us to
hypothesize that the increase in the levels of expression
of TGF-b during tumor progression stimulates the
downregulation of TbRs, both in the tumor itself and in
stroma (CAFs), which results in the TbR-mediated
reduction of apoptosis. Accordingly, loss of functional
TbRII and TbRIII signaling may contribute to apoptotic
escape and tumorigenesis.
At present, three main strategies are used to target
CAFs during cancer therapy: (a) targeting of the CAF
signals that initiate or promote tumor growth, invasion,
and metastasis; (b) targeting of the tumor signals that
are responsible for the development of “adequate”
tumor fibroblasts; and (c) elimination of the CAFs
themselves, to abolish all interactions among heterotypic
cell types [21]. However, the tumor-host interaction
microenvironment is a large and complex network;
therefore, it remains questionable whether the use of
one single factor (such as antibodies) is efficient in can-
cer therapy. Two large randomized trials in SCLC failed
to show any benefits for inhibitor treatment [24]. Thus,
it is necessary to exploit novel strategies that use CAFs
Table 2 Clinical and Pathological Data of OSCC Samples Used for CAF Cultivation
Sample No Sex Age Location Histological
type
TNM classification Clinical stage
01 Female 38 Tongue Well diff. SCC T1N0M0 I
02 Female 57 Tongue Well diff. SCC T1N0M0 I
03 Female 64 Tongue Mod. diff. SCC T1N0M0 I
04 Male 50 Oral floor Poor diff. SCC T2N2M0 IV
05 Male 62 Gingival Mod. diff. SCC T2N2M0 II
06 Female 71 Gingival Mod. diff. SCC T2N2M0 II
07 Male 50 Buccal mucosa Mod. diff. SCC T1N0M0 I
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Figure 4 Identification of oral CAFs and NFs. The morphological characteristics of CAFs changed significantly compared with what was
observed in NFs. CAFs showed positive staining for vimentin and a-SMA and were negative for cytokeratin. The positive control (human normal
keratinocytes HaCat) is shown for cytokeratin stain.
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Figure 5 Quantitative real-time PCR analysis of the mRNA levels of TbRI, TbRII, and TbRIII in CAFs and in CAFs in response to TGF-b1
(10 ng/ml) stimulation. (A) The expression levels of TbRI were not significantly different in CAFs and NFs (P = 0.362); TGF-b1 treatment didn’t
change the TbRI levels in CAFs or in NFs. (B) TbRII mRNA expression was reduced in CAFs compared with NFs (*P = 0.004); The levels of
expression of TbRII in oral CAFs or NFs were significantly decreased after treatment with 10 ng/ml TGF-b1 (*P = 0.0025). (C) TbRIII mRNA
expression in CAFs was also significantly different from that of the control group (**P = 0.001). The levels of expression of TbRIII in oral CAFs or
NFs were also significantly decreased after treatment with 10 ng/ml TGF-b1 (**P = 0.0035). (D, E) The maximal downregulation in oral CAFs with
TGF-b1 was observed at 6-12 h. (F, G) The maximal downregulation in NFs with TGF-b1 was observed at 6 h.
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Figure 6 Western blot analysis of the TbR proteins in NFs (N), CAFs (C), and in TGF-b-conditioned CAFs and NFs. Western blot analysis
revealed that the levels of expression of TbRI were increased in TGF-b-conditioned CAFs compared with untreated CAFs. The expression levels
of TbRII and TbRIII were significantly decreased significantly in TGF-b-conditioned CAFs and TGF-b-conditioned NFs.
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as targets in anticancer therapies. In the current study,
we demonstrated that the expression of TbRII and
TbRIII in oral epithelium and CAFs played an important
role in tumorigenesis. In addition, the restoration of the
expression levels of TbRII and TbRIII seems more feasi-
ble than prior strategies.
Taken together, these data suggest that the loss of the
expression of TbRII and TbRIII in oral epithelium and
stroma (CAFs) is a common event in OSCC patients.
Therefore, we strongly believed that TbRII and/or
TbRIII may be used as predictors of tumorigenesis and
severity and represent adequate therapeutic targets.
However, the understanding of the precise mechanisms
involved falls short of what would be required for the
development of practical clinical applications. Moreover,
the restoration of the expression levels of TbRIII and
TbRII in cancerous tissues of the oral mucosa may serve
as a novel target for the treatment of oral carcinoma.
Conclusions
The expression of both TbRII and TbRIII was signifi-
cantly downregulated in oral epithelium and stroma
(CAFs) in OSCC. Exogenous TGF-b1 could downregu-
late both TbRII and TbRIII in oral CAFs and in NFs.
Moreover, the restoration of the expression levels of
TbRIII and TbRII in cancerous tissues of the oral
mucosa may serve as a novel target for the treatment of
oral carcinoma.
Acknowledgements
This study was supported by grants from the National Natural Science
Foundation of China (No. 30872873), the Doctoral Fund of the Ministry of
Education of China (No. 20070610067).
Author details
1State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, Sichuan,
China. 2The Station Key Lab of Biotherapy, Sichuan University, Sichuan,
China. 3Department of Oral Pathology, West China Hospital of Stomatology,
Sichuan University, Sichuan, China. 4Department of Oral Oncology, West
China Hospital of Stomatology, Sichuan University, Sichuan, China.
5Department of Oral Medicine, West China Hospital of Stomatology, Sichuan
University, Sichuan, China.
Authors’ contributions
WXM carried out the experimental studies and drafted and completed the
manuscript. QJX participated in the design of the study and performed the
statistical analysis. LYW, SXC, XH and LZ participated the tissue collected and
tumor pathological characteristics. HMZ and QHG conceived of the study
and participated in the design and coordination as well as helped to draft
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 August 2010 Accepted: 28 February 2011
Published: 28 February 2011
References
1. Elliott RL, Blobe GC: Role of transforming growth factor Beta in human
cancer. J Clin Oncol 2005, 23:2078-2093.
2. Attisano L, Wrana JL: Signal transduction by the TGF-beta superfamily.
Science 2002, 296:1646-1647.
3. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE: Genetic
alterations of the transforming growth factor beta receptor genes in
pancreatic and biliary adenocarcinomas. Cancer Res 1998, 58:5329-5332.
4. Munoz-Antonia T, Muro-Cacho C, Sharma S, Cantor A, Bepler G: Expression
of TGFbeta type-II receptor in association with markers of proliferation
and apoptosis in premalignant lung lesions. Cancer 2007, 110:1527-1531.
5. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC: The type III
transforming growth factor-beta receptor as a novel tumor suppressor
gene in prostate cancer. Cancer Res 2007, 67:1090-1098.
6. Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, Wood CG: Type III
transforming growth factor-beta (TGF-beta) receptor mediates apoptosis
in renal cell carcinoma independent of the canonical TGF-beta signaling
pathway. Clin Cancer Res 2008, 14:5722-5730.
7. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT:
Presentation, treatment, and outcome of oral cavity cancer: a National
Cancer Data Base report. Head Neck 2002, 24:165-180.
8. Mincione G, Di Marcantonio MC, Artese L, Vianale G, Piccirelli A, Piccirilli M,
Perrotti V, Rubini C, Piattelli A, Muraro R: Loss of expression of TGF-ß1,
TßRI, and TßRII correlates with differentiation in human oral squamous
cell carcinomas. Int J Oncol 2008, 32(2):323-31.
9. Hui P, Shintaniy S, Kim Y, Wong DT: Loss of p12CDK2-AP1 Expression in
human oral squamous cell carcinoma with disrupted transforming
growth factor-β-Smad signaling pathway. Neoplasia 2006, 8:1028-1036.
10. Ostman A, Augsten M: Cancer-associated fibroblasts and tumor growth-
bystanders turning into key players. Current Opinion in Genetics &
Development 2009, 19:67-73.
11. Kiaris H, Trimis G, Papavassiliou AG: Regulation of tumor-stromal fibroblast
interactions: implications in anticancer therapy. Current Medicinal
Chemistry 2008, 15:3062-3067.
12. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR:
Carcinoma-associated fibroblasts direct tumor progression of initiated
human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
13. Orimo A, Gupta PB, Sgrol DC, Arenzana-Seisdedos F, Delaunay T, Naeem R,
Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive
human breast carcinomas promote tumor growth and angiogenesis
through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
14. Liu Y, Hu T, Shen J, Li SF, Lin JW, Zheng XH, Gao QH, Zhou HM:
Separation, cultivation and biological characteristics of oral carcinoma-
associated fibroblasts. Oral Dis 2006, 12:375-380.
15. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer
initiation and progression. Nature 2004, 432:332-337.
16. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A: TGF-
beta receptor 2 downregulation in tumour-associated stroma worsens
prognosis and high-grade tumours show more tumour-associated
macrophages and lower TGF-beta1 expression in colon carcinoma: a
retrospective study. BMC Cancer 2007, 7:156.
17. Sousa AM, Liu T, Guevara O, Stevens J, Fanburg BL, Gaestel M, Toksoz D,
Kayyali US: Smooth muscle alpha-actin expression and myofibroblast
differentiation by TGFbeta are dependent upon MK2. J Cell Biochem
2007, 100:1581-1592.
18. Gordon KJ, Mei D, Chislock EM, Field TA, Blobe GC: Loss of type III
transforming growth factor b receptor expression increases motility and
invasiveness associated with epithelial to mesenchymal transition during
pancreatic cancer progression. Carcinogenesis 2008, 29:252-262.
19. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P,
Moeller BJ, Marks JR, Blobe GC: The type III TGF-beta receptor suppresses
breast cancer progression. J Clin Invest 2007, 117:206-217.
20. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A,
Ji B, Evans DB, Logsdon CD: Cancer-associated stromal fibroblasts
promote pancreatic tumor progression. Cancer Res 2008, 68:918-926.
21. Micke P, Ostman A: Tumour-stroma interaction: cancer-associated
fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004, 45:
S163-S175.
22. Kang Y: A self-enabling TGFbeta response coupled to stress signaling:
Smad engages stress response factor ATF3 for Id1 repression in
epithelial cells. Mol Cell 2003, 11:915-926.
23. Hempell N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG,
Blobe GC: Expression of the type III TGF-b receptor is negatively
regulated by TGF-beta. Carcinogenesis 2008, 29:905-912.
Meng et al. BMC Cancer 2011, 11:88
http://www.biomedcentral.com/1471-2407/11/88
Page 12 of 13
24. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V,
Smylie M, Rubin S, Martins H, Lamont A, et al: Prospective, randomized,
double-blind, placebo-controlled trial of marimastat after response to
first-line chemotherapy in patients with small-cell lung cancer: a trial of
the National Cancer Institute of Canada-Clinical Trials Group and the
European Organization for Research and Treatment of Cancer. J Clin
Oncol 2002, 20:4434-4439.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/88/prepub
doi:10.1186/1471-2407-11-88
Cite this article as: Meng et al.: Downregulation of TGF-beta receptor
types II and III in oral squamous cell carcinoma and oral carcinoma-
associated fibroblasts. BMC Cancer 2011 11:88.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Meng et al. BMC Cancer 2011, 11:88
http://www.biomedcentral.com/1471-2407/11/88
Page 13 of 13
